Movement disorders:大脑代谢与前驱和早期帕金森病中的多巴胺能失调有关

2022-08-23 Freeman MedSci原创

在前驱期和早期PD阶段,与多巴胺能神经支配有关的各个脑区的代谢反应的轨迹是不同的。

孤立的快速眼动睡眠行为障碍(iRBD)被认为是帕金森病(PD)的最可靠的前驱标志。大量证据表明,iRBD患者已经有神经退行性改变,包括黑质多巴胺缺失和大脑代谢异常。多巴胺转运体(DAT)成像研究显示,iRBD的DAT可用性是PD早期阶段和正常状况之间的中间水平,表明iRBD患者在黑质多巴胺能投射方面有早期的神经退行性。在代谢活动方面,iRBD患者通常表现为额叶皮层、海马体和盆腔的相对代谢增加,枕叶、顶叶和颞叶皮层的代谢减少,这被称为快速眼动睡眠行为障碍(RBD)相关的代谢模式。然而,这些亚区的代谢活动似乎随着疾病的进展而发生异质性改变。

图1: 论文封面图


尽管多巴胺能和代谢成像标志物被用于iRBD患者,以了解该疾病的病理机制并预测表象转化,但只有有限的证据表明这两种成像标志物之间的相互作用。以前的研究表明,PD患者的纹状体多巴胺能功能与前额叶和顶枕叶皮层的代谢活动呈正相关,与小脑和盆腔的代谢活动呈负相关,尽管各研究的结果存在一些矛盾。

在最近一项关于路易体痴呆症(DLB)的研究中,纹状体多巴胺的可用性与基底神经节和边缘系统中明显的代谢增加之间存在负相关。这些观察结果可能提供了有关针对多巴胺能失调的病理和补偿性代谢反应的关键信息。然而,目前仍不清楚这种变化是否出现在疾病的前驱阶段,以及大脑代谢活动如何随着多巴胺能缺乏的进展而发生转变。


藉此,韩国Inha University College of Medicine的 Ryul Kim等人,通过横断面和纵向数据分析,评估了黑质多巴胺能缺失与iRBD和早期PD患者的脑部葡萄糖代谢之间的关系。在横断面分析中,他们假设黑质多巴胺能变性的进展是一个连续的过程,从正常状态到iRBD,然后到新的PD与RBD。

在这种假设下,他们首先进行了基于区域的分析,以调查新发、未用药的PD与可能的RBD(denovoPD)患者、iRBD患者和健康对照组中纹状体的DAT可用性和葡萄糖代谢情况。接下来,他们进行了体素分析,以调查纹状体多巴胺能损失和全脑代谢活动之间的联系。

最后,调查了多巴胺能丧失的不同阶段的代谢连接模式。在纵向分析中,他们利用4年的随访数据探讨了iRBD患者纹状体DAT可用性和大脑葡萄糖代谢的变化之间的关系。

这项队列研究包括28名经多导睡眠图证实的iRBD患者、24名可能有快速眼动睡眠行为障碍的新发PD患者(denovoPD)和28名健康对照者(HCs),他们接受了两次18F-氟脱氧葡萄糖(所有参与者)和18F-N-3-氟丙基-2β-羧基甲氧基-3β-(4-碘苯基)-降压剂(除了一名denovoPD患者和15名HCs)的正电子发射体层扫描。

他们分析了纹状体和体素的全脑葡萄糖代谢与黑质多巴胺能完整性的关系,并比较研究了各组之间的全脑代谢连接。他们还评估了iRBD组4年来的纵向代谢变化与进行性多巴胺能失调的关系。

图2:论文结果图

从HCs到iRBD,最后到新发PD,多巴胺能的完整性与尾状体的代谢活动呈正相关,而在后置放脑中则观察到负相关。在iRBD组中,下眶额叶皮层的代谢活动在基线时有增加,但在4年的随访中,在上眶额叶皮层和上额回新观察到负相关。

与denovoPD组和HC组相比,iRBD组的顶枕部皮层的区域内和区域间的代谢连接性增强。在iRBD组,通过推进多巴胺能去势,整体代谢连接得到加强,基底神经节-前额连接也得到加强。

该研究的重要意义在于发现了:在前驱期和早期PD阶段,与多巴胺能神经支配有关的各个脑区的代谢反应的轨迹是不同的

 


原文出处:
Kim R, Kim H, Kim YK, et al. Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson’s Disease. _Movement Disorders_. Published online August 12, 2022:mds.29177. doi:[10.1002/mds.29177](https://doi.org/10.1002/mds.29177)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013946, encodeId=458a201394675, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 16 12:16:25 CST 2022, time=2022-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077717, encodeId=3cc420e7717ca, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Apr 27 23:16:25 CST 2023, time=2023-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878571, encodeId=a33a18e857185, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Feb 06 17:16:25 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784538, encodeId=64341e84538d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 01:16:25 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738149, encodeId=3d051e38149c8, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Fri Apr 07 05:16:25 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707697, encodeId=11f71e0769776, content=<a href='/topic/show?id=8838846948e' target=_blank style='color:#2F92EE;'>#脑代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84694, encryptionId=8838846948e, topicName=脑代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9331479869, createdName=12498877m108暂无昵称, createdTime=Mon Apr 10 18:16:25 CST 2023, time=2023-04-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013946, encodeId=458a201394675, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 16 12:16:25 CST 2022, time=2022-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077717, encodeId=3cc420e7717ca, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Apr 27 23:16:25 CST 2023, time=2023-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878571, encodeId=a33a18e857185, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Feb 06 17:16:25 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784538, encodeId=64341e84538d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 01:16:25 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738149, encodeId=3d051e38149c8, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Fri Apr 07 05:16:25 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707697, encodeId=11f71e0769776, content=<a href='/topic/show?id=8838846948e' target=_blank style='color:#2F92EE;'>#脑代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84694, encryptionId=8838846948e, topicName=脑代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9331479869, createdName=12498877m108暂无昵称, createdTime=Mon Apr 10 18:16:25 CST 2023, time=2023-04-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2013946, encodeId=458a201394675, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 16 12:16:25 CST 2022, time=2022-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077717, encodeId=3cc420e7717ca, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Apr 27 23:16:25 CST 2023, time=2023-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878571, encodeId=a33a18e857185, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Feb 06 17:16:25 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784538, encodeId=64341e84538d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 01:16:25 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738149, encodeId=3d051e38149c8, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Fri Apr 07 05:16:25 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707697, encodeId=11f71e0769776, content=<a href='/topic/show?id=8838846948e' target=_blank style='color:#2F92EE;'>#脑代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84694, encryptionId=8838846948e, topicName=脑代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9331479869, createdName=12498877m108暂无昵称, createdTime=Mon Apr 10 18:16:25 CST 2023, time=2023-04-10, status=1, ipAttribution=)]
    2023-02-06 anminleiryan
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013946, encodeId=458a201394675, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 16 12:16:25 CST 2022, time=2022-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077717, encodeId=3cc420e7717ca, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Apr 27 23:16:25 CST 2023, time=2023-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878571, encodeId=a33a18e857185, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Feb 06 17:16:25 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784538, encodeId=64341e84538d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 01:16:25 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738149, encodeId=3d051e38149c8, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Fri Apr 07 05:16:25 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707697, encodeId=11f71e0769776, content=<a href='/topic/show?id=8838846948e' target=_blank style='color:#2F92EE;'>#脑代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84694, encryptionId=8838846948e, topicName=脑代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9331479869, createdName=12498877m108暂无昵称, createdTime=Mon Apr 10 18:16:25 CST 2023, time=2023-04-10, status=1, ipAttribution=)]
    2023-01-29 cmsvly
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013946, encodeId=458a201394675, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 16 12:16:25 CST 2022, time=2022-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077717, encodeId=3cc420e7717ca, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Apr 27 23:16:25 CST 2023, time=2023-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878571, encodeId=a33a18e857185, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Feb 06 17:16:25 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784538, encodeId=64341e84538d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 01:16:25 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738149, encodeId=3d051e38149c8, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Fri Apr 07 05:16:25 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707697, encodeId=11f71e0769776, content=<a href='/topic/show?id=8838846948e' target=_blank style='color:#2F92EE;'>#脑代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84694, encryptionId=8838846948e, topicName=脑代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9331479869, createdName=12498877m108暂无昵称, createdTime=Mon Apr 10 18:16:25 CST 2023, time=2023-04-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2013946, encodeId=458a201394675, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Dec 16 12:16:25 CST 2022, time=2022-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2077717, encodeId=3cc420e7717ca, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Thu Apr 27 23:16:25 CST 2023, time=2023-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878571, encodeId=a33a18e857185, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Mon Feb 06 17:16:25 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784538, encodeId=64341e84538d5, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sun Jan 29 01:16:25 CST 2023, time=2023-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738149, encodeId=3d051e38149c8, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Fri Apr 07 05:16:25 CST 2023, time=2023-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707697, encodeId=11f71e0769776, content=<a href='/topic/show?id=8838846948e' target=_blank style='color:#2F92EE;'>#脑代谢#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84694, encryptionId=8838846948e, topicName=脑代谢)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa9331479869, createdName=12498877m108暂无昵称, createdTime=Mon Apr 10 18:16:25 CST 2023, time=2023-04-10, status=1, ipAttribution=)]

相关资讯

Movement disorders:血清MicroRNAs可预测孤立的快速眼动睡眠行为障碍和路易体疾病

仅特定的miRNA生物特征就有希望作为IRBD患者的进展生物标志物来预测PD和DLB的临床结果。

Science:GPNMB可能是帕金森病的重要的生物标志物

研究人员报告说,基于计算、细胞生物学和人体组织的研究将 GPNMB 确定为帕金森病 (PD) 的风险基因和潜在治疗靶点。 PD 是一种使人衰弱的进行性神经退行性脑部疾病,影响着全世界数百万人。 疾病的

Movement Disordres-针对突触核蛋白的新型PD药物,效果如何?

可接受的安全性/耐受性特征和可预测的PK支持继续开发UCB0599用于减缓PD的进展。

Movement Disordres-帕金森病患者血浆中糖磷脂的变化与葡萄糖酰甘油水平无关

在有和没有GlcCer变化的患者中检测到血浆中多种GSL异常,表明脂质平衡有更广泛的转变。

Phytomedicine:地黄饮通过减轻外周炎症保护帕金森病模型多巴胺能神经元

验证中药配方地黄饮(DHY)对帕金森病(PD)小鼠模型的治疗作用,并探讨其潜在的分子机制。

拓展阅读

European Radiology:使用多模态PET/MRI放射组学识别帕金森病和多系统萎缩

放射组学是指从医学影像中高通量提取丰富的影像信息,以辅助医生做出最准确的诊断。现阶段,放射组学已广泛应用于肿瘤学研究,如肿瘤的诊断、分级、疗效评估、预后预测等。

AAN 2024大会盛况回顾,带您领略神经病学新高度!

作为神经科医生,您一定对AAN 2024年大会充满期待。我们为您精心整理了大会内容解读,包括最新研究成果、临床实践经验和未来发展趋势等,让您足不出户就能领略到大会的精彩盛况!点击立即查看别错过!

AAN 2024:突触核蛋白皮肤活检在帕金森病的初步诊断的临床实践

帕金森病早期准确诊断是一项尚未满足的重大需求,这对于早期干预和预后改善有着重要的影响。

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。